Kayothera, an early-stage therapeutics company founded by Mark Esposito and Yibin Kang, is working to give hope to some of the most vulnerable cancer patients. Now the company’s aspirations are being bolstered by significant seed funding received from the New Jersey Health Foundation (NJHF).
MOL BIO Assistant Professor Martin Jonikas and colleagues are investigating a gene important for regulating pyrenoid shape and number, and enhances our understanding of this essential component of the global carbon cycle.
